Targeted Brain Delivery via MR-DTI Planning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating Alzheimer's disease do not effectively target the delivery of therapeutic substances to specific brain regions, such as the hippocampus, where beta-amyloid plaques and neurofibrillary tangles accumulate, leading to inadequate treatment of the disease.
Innovation Solution
A system and method for planned targeted delivery of therapeutic agents, such as anti-beta amyloid antibodies, to the brain using magnetic resonance diffusion tensor imaging (MR-DTI) scans to calculate diffusion tensors, agent distribution, and concentration, allowing for precise planning and execution of agent delivery to achieve desired concentrations and distributions within the target region.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If therapeutic agents are administered systemically to treat Alzheimer's disease, then the treatment can reach all brain regions, but the concentration of the agent in specific target regions (such as the hippocampus) is insufficient to effectively clear amyloid plaques
Solution Approach 1:
The patent divides the brain into specific target regions (such as the hippocampus) and uses separate catheters for each region, allowing independent delivery of therapeutic agents to each segment. This segmentation enables high concentration delivery to specific areas without requiring systemic administration, thereby resolving the contradiction between achieving sufficient local concentration and avoiding complex systemic delivery systems.
Solution Approach 2:
The patent introduces catheters as intermediary devices that directly connect the therapeutic agent source to the target brain regions. These catheters serve as mediators that bypass the blood-brain barrier and systemic distribution, delivering agents directly to the hippocampus and other affected areas with controlled high concentrations, thus resolving the concentration insufficiency problem without requiring complex systemic modification.
2Reliability
If anti-beta amyloid antibodies are administered to clear amyloid plaques, then disease progression can be halted, but severe side effects (meningoencephalitis) occur when fragments of amyloid protein are used for vaccination
Solution Approach 1:
The patent extracts only the necessary therapeutic component (anti-beta amyloid antibodies) from the complete vaccination protocol that caused side effects. By removing the amyloid protein fragments that triggered meningoencephalitis and retaining only the therapeutic antibodies, the system achieves effective plaque clearance without the harmful side effects, thus resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The patent converts the harmful effect of amyloid protein fragments (which caused meningoencephalitis) into a benefit by using only the therapeutic antibodies derived from the same immunization process. The harmful fragments are excluded, while the beneficial antibody production is harnessed and delivered directly to clear plaques, transforming a potentially harmful approach into a safe and effective treatment.
3Manufacturing precision
If therapeutic agents are delivered to the brain using conventional methods, then the delivery process is simple, but the distribution and concentration of the agent cannot be precisely controlled in specific brain regions
Solution Approach 1:
The patent incorporates imaging guidance (such as MRI or CT) to visualize catheter placement and monitor agent distribution in real-time. This feedback mechanism allows the operator to adjust catheter position and delivery parameters to achieve precise concentration control in target regions, resolving the contradiction between precision and complexity by providing visual confirmation that justifies the enhanced system complexity.
Solution Approach 2:
The patent replaces conventional mechanical injection methods with a more sophisticated delivery system that uses imaging guidance and controlled infusion mechanisms. This substitution of mechanical simplicity with a guided, monitored system enables precise control of agent distribution and concentration, achieving manufacturing-level precision in therapeutic delivery despite increased system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables effective treatment of Alzheimer's disease by ensuring precise delivery of therapeutic agents to the affected brain regions, potentially halting disease progression by clearing amyloid plaques and tangles, while minimizing side effects.
Implementation Method 1
magnetic resonance diffusion tensor imaging (MR-DTI) scans
Implementation Method 2
diffusion tensor imaging (MR-DTI) scans to calculate diffusion tensors
Data Source
AI summary
A system and method for treating Alzheimer's disease by delivery of an agent within the brain. At least one image of a target region is acquired, and at least one magnetic resonance diffusion tensor imaging (MR-DTI) scan of the target region is acquired. A diffusion tensor is calculated from the at least one MR-DTI scan, and at least one of an agent distribution and an agent concentration from the images and the calculated diffusion tensor is calculated. Using at least one of the calculated diffusion tensor, the images, the calculated agent distribution, and the calculated agent concentration, the placement of a delivery instrument is planned to deliver the agent to the target region to achieve a desired agent concentration and/or agent distribution within the target region.